Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to 2.93%.

  • Integra Lifesciences Holdings' EBIT Margin rose 50700.0% to 2.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.26%, marking a year-over-year decrease of 311100.0%. This contributed to the annual value of 1.76% for FY2024, which is 54700.0% down from last year.
  • Latest data reveals that Integra Lifesciences Holdings reported EBIT Margin of 2.93% as of Q3 2025, which was up 50700.0% from 123.36% recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' EBIT Margin ranged from a high of 17.04% in Q4 2022 and a low of 123.36% during Q2 2025
  • For the 5-year period, Integra Lifesciences Holdings' EBIT Margin averaged around 1.19%, with its median value being 8.53% (2021).
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 78500bps in 2021, then tumbled by -1226300bps in 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' EBIT Margin (Quarter) stood at 14.36% in 2021, then grew by 19bps to 17.04% in 2022, then crashed by -47bps to 9.08% in 2023, then dropped by -11bps to 8.05% in 2024, then crashed by -64bps to 2.93% in 2025.
  • Its EBIT Margin was 2.93% in Q3 2025, compared to 123.36% in Q2 2025 and 4.05% in Q1 2025.